{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:54:40Z","timestamp":1785034480103,"version":"3.55.0"},"reference-count":0,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.4155\/fmc.09.115","type":"journal-article","created":{"date-parts":[[2009,11,13]],"date-time":"2009-11-13T11:44:15Z","timestamp":1258112655000},"page":"1395-1398","source":"Crossref","is-referenced-by-count":5,"title":["Interview with J\u00fcRg Zimmermann, Global Head of Oncology & Exploratory Chemistry at Novartis"],"prefix":"10.1080","volume":"1","author":[{"given":"J\u00fcrg","family":"Zimmermann","sequence":"first","affiliation":[{"name":"Novartis Pharma AG, WKL-136.6.24, Postfach, CH-4002, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,11,13]]},"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.09.115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:49:48Z","timestamp":1716493788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.09.115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.4155\/fmc.09.115"],"URL":"https:\/\/doi.org\/10.4155\/fmc.09.115","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}